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Abstract Polysomnography (PSG) is considered the gold
standard for diagnosis of non-rapid eye movement
(NREM) parasomnias, however its diagnostic yield has
been rarely reported. We aimed to assess the diagnostic
value of polysomnography in different categories of
patients with suspected NREM parasomnia and define
variables that can affect the outcome. 124 adults referred
for polysomnography for suspected NREM parasomnia
were retrospectively identified and divided into clinical
categories based on their history. Each polysomnography
was analysed for features of NREM parasomnia or differ-
ent sleep disorders and for presence of potential precipit-
ants. The impact on the outcome of number of recording
nights and concomitant consumption of benzodiazepines
and antidepressants was assessed. Overall, PSG confirmed
NREM parasomnias in 60.5 % patients and showed a dif-
ferent sleep disorder in another 16 %. Precipitants were
found in 21 % of the 124 patients. However, PSG showed
limited value when the NREM parasomnia was clinically
uncomplicated, since it rarely revealed a different diagno-
sis or unsuspected precipitants (5 % respectively), but
became essential for people with unusual features in the
history where different or overlapping diagnoses (18 %) or
unsuspected precipitants (24 %) were commonly identi-
fied. Taking benzodiazepines or antidepressants during the
PSG reduced the diagnostic yield. PSG has a high diag-
nostic yield in patients with suspected NREM parasomnia,
and can reveal a different diagnosis or precipitants in over
40 % of people with complicated or atypical presentation
or those with a history of epilepsy. We suggest that PSG
should be performed for one night in the first instance, with
leg electrodes and respiratory measurements and after
benzodiazepine and antidepressant withdrawal.
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Introduction
Parasomnias are undesirable physical events or experiences
that occur during sleep [1] and are classified by the sleep
stage from which they arise [1, 2]. NREM parasomnias
arise from non-rapid eye movement (NREM) sleep, typi-
cally from slow-wave sleep (SWS), and include three
typical behaviours–confusional arousals, sleep walking and
sleep terrors. They are also termed ‘‘arousal disorders’’
since the episodes usually occur during the transition from
SWS to an arousal phase or awakening [1–3].
NREM parasomnia typically occurs in childhood
although an onset or persistence into adult life is not
uncommon [1, 2, 4–7]. Their diagnosis is essentially clin-
ical and often based on patient and bed-partner interviews.
ICSD-2, and recently ICSD-3, propose essential diagnostic
criteria for each of the three subtypes above [1, 2].
Typical NREM parasomnia is usually considered a
benign condition, easy to recognise and treat. However,
NREM parasomnia diagnosis can be challenging when the
clinical history is unusual because of the age of onset, the
time or duration of the episodes at night, the presence of
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suspected precipitating factors (such as periodic limb
movements-PLMS or obstructive respiratory events),
the unresponsiveness to conventional therapy or the
occurrence of complex or dangerous behaviours [1, 8–12].
Indeed, on occasion, NREM parasomnia can be dangerous,
resulting in injurious accidents or, not infrequently, can
lead to sleep disruption [1, 10].
Clinical diagnosis may be especially challenging when
there are similarities to other paroxysmal nocturnal events
such as REM parasomnia or epilepsy [13–15], in particular
in those patients in whom multiple conditions coexist
[16–18].
During the last two decades increasing attention has
been placed on clinical methods to distinguish nocturnal
frontal lobe epilepsy from parasomnia [19–21], but, so far,
no clinical algorithm or clinical questionnaire has been
shown to differentiate reliably between these two different
groups of sleep disorders [22–24]. Therefore overnight
video-polysomnography (PSG) is still considered the gold
standard test [23].
According to the American Academy of Sleep Medicine
(AASM) [1], PSG can provide support for the clinical
diagnosis of NREM parasomnia by documenting multiple
arousals from SWS unaccompanied by parasomnia
behaviours or strong support by documenting arousals from
SWS accompanied by behaviours typical of arousal
disorders.
Although PSG is often used to assist the clinician in the
diagnosis of NREM parasomnia, the diagnostic value of the
test has not been clearly established; there have only been a
few studies [25–28] and some did not differentiate between
parasomnia type [28].
The AASM published practice parameters for the indi-
cation of PSG for different sleep disorders, including par-
asomnia [11, 12].
However, the evidence supporting the guideline’s rec-
ommendations is somewhat conflicting and mainly based
on small cases series and not always directly related to
routine practice [11, 12, 29].
Moreover, the guidelines do not include information on
how many nights of PSG should be performed and whe-
ther, or which kind, of drug discontinuations should be
instigated before the overnight recording.
We aimed to define the diagnostic value of PSG among
different clinical categories of patients referred for PSG to
a single Sleep Centre for suspected NREM parasomnia, in
order to assess how often PSG is able to facilitate the
diagnosis, either confirming NREM parasomnia or ruling
out alternative diagnoses or precipitant factors. Such
information will help determine which groups of patients
may benefit from an overnight recording and avoid
unnecessary investigations of people in whom PSG will be
of limited value.
We also aimed to clarify the confounding effect of
concomitant consumption of the most widely used drugs
for NREM parasomnia (antidepressants and benzodiaze-
pine receptor agonists) on PSG results and to establish the
utility of performing more than one night of recording in
order to increase the diagnostic yield.
Methods
Patients and clinical categories
Medical records of a total of 592 consecutive patients who
underwent one or more sleep studies at the National Hos-
pital for Neurology and Neurosurgery over a period of
4 years (January 2009–December 2012) were retrospec-
tively reviewed.
Among them, 126 patients were referred for PSG for
suspected NREM parasomnia by sleep specialists, whereas
466 were patients referred for PSG for other types of sleep
disorders.
Of 126 patients referred for suspected NREM para-
somnia only patients who underwent one or two nights of
diagnostic PSG were considered. Patients who underwent
more than two nights of recording or repeated the study
after having already been diagnosed with NREM para-
somnia were excluded from the analysis. For patients that
underwent more than one PSG study within the period
above, only the first study was considered.
Therefore two patients were excluded from the recruit-
ment, one because of three nights recording and another
because this was a follow-up PSG in a patient already
diagnosed with NREM parasomnia.
124 patients and consequently as many sleep studies
were analysed. Based on the clinical history at the time of
presentation and according to the ICSD-2 clinical criteria
[1] the 124 patients were divided into four main categories
(Table 1).
Frequency of the presumed NREM parasomnia episodes
was not considered as a factor against the clinical diagnosis
of NREM parasomnia when the history was otherwise
typical.
An arbitrary cut off of 16 years of age was chosen to
differentiate childhood and youth onset of the episodes
from an onset in adult life.
Sleep analysis
All the sleep studies were carried out and scored by
experienced clinical physiologists (neurophysiology) and
then by clinicians specialising in sleep disorders, according
to the AASM ‘‘Manual for the Scoring of Sleep and
Associated Events’’ [30].
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All patients underwent polysomnography using full
10–20 electrode placement [31] with additional polygraphy
electrodes including bilateral electrooculogram referred to
cross-linked mastoid electrodes, bilateral masseter EMG,
submentalis EMG and bilateral tibialis anterior EMG. Pulse
oximetry and airflow were also recorded if clinically indi-
cated. The data were acquired and analysed using Nicolet
(Viasys) equipment and software. The data were scored in
30-s epochs, and classified as light sleep, deep sleep, REM
sleep or movement. Oxygen desaturations were noted as
significant if there was a drop of more than 4 % from
baseline. Episodes of hypopnoea or apnoea were analysed.
All arousals or awakenings were annotated. We scored
as arousal each event characterised by an abrupt shifting of
EEG frequency into alpha, theta or faster frequency, other
than spindles, that lasted at least 3 s, according to the
AASM ‘‘Manual for the Scoring of Sleep and Associated
Events’’ [30]. Arousals were classified as spontaneous
when not determined by any clear underlying event such as
noise, light or other environmental disturbances.
Each sleep study was classified as decisive (arousals
from SWS accompanied by NREM parasomnia behav-
iours), supportive (spontaneous arousals from SWS
accompanied by more subtle behaviours such as raising the
head, sympathetic activation, such as tachycardia, rhythmic
delta activity on EEG but no epileptiform activity) or
inconclusive (none of the above) for diagnosis of NREM
parasomnia [1].
Alternative and overlapping diagnoses were also inves-
tigated based on the events recorded during the overnight
study according to ICSD-2 [1].
Diagnosis of epilepsy was made if unequivocal interictal
epileptiform EEG abnormality or clear epileptic events
were captured.
We also identified any precipitant event such as PLMS
or respiratory events as clinically significant when they
demonstrated to have a clinical impact on the patient’s
sleep stability, either causing an arousal or awakening or
sleep stage shifting.
Assessment of other variables
Concomitant consumption of benzodiazepine-receptor
agonists (BZD or newer BzRAs) or any type of antide-
pressant (serotonin reuptake inhibitors-SSRIs, tricyclic
antidepressants and serotonin–norepinephrine reuptake
inhibitors-SNRIs) at the time of the sleep study was also
investigated for each patient and correlated with outcome
of the sleep study.
The utility of performing a second night recording, to
increase the yield of the study, was also evaluated in
patients that underwent two nights of recording. In par-
ticular, we looked at the episodes recorded over the first
and the second night and classified as diagnostic the night
on which we captured any clear, typical and useful event
for the diagnosis. If one or more clear and typical episodes
were present over both nights, we classified as diagnostic
only the first night when the second night recording did not
add any further information compared to the previous
night.
Statistical analysis
Statistical analysis was performed using the SPSS V.22
statistical software package.
Fisher’s exact test was used to test correlations between
outcome (positive–negative) and other categorical vari-
ables such as main categories belonging (1, 2, 3, 4), age at
onset ([ or B of 16 years), antidepressant/BDZ con-
sumption (yes or no) and nights of recording (one or two).
Fisher’s exact test was also used to test correlation
between presence of overlapping/different diagnoses or
precipitants (yes or no) and main categories belonging (1,
2, 3, 4). Significance thresholds were set at p \ 0.05. All
tests were two tailed.
Results
Population
Among 124 patients referred for an overnight sleep study
with a query of NREM parasomnia, there were 60 males
and 64 females, with a mean age at time of consultation of
Table 1 Clinical categories made to group 124 patients referred for
suspected NREM parasomnia, according to ICSD-2 clinical criteria
Clinical categories
(1) Typical, uncomplicated NREM parasomnia
For time and duration of the episodes at night
Age at onset B16 years
(2) Typical NREM parasomnia but complicated by
(a) Injurious behaviour
(b) Precipitants (OSAS, PLMS)
(c) Unresponsiveness to conventional therapy
(3) Unusual/atypical NREM parasomnia, not clinically defined
because of
(a) Age at onset [16 years
(b) Thought to be seizure related
(c) Overlapping features with other sleep disorders
(RBD/narcolepsy/psychiatric/insomnia).
(4) History of epilepsy in addition to suspected NREM
parasomnia
OSAS obstructive sleep apnoea syndrome, PLMS periodic limb
movements syndrome, RBD REM sleep behaviour disorder
J Neurol (2015) 262:385–393 387
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37 ± 1 years (range 18–80 years) and a median age of
34 years.
Most of the patients belonged to the third category
(n = 73). This was either due to unusual features such as
the age at onset [16 years (category 3.a, n = 12); the
episodes were thought to be seizure related (category 3.b,
n = 16); or the diagnosis was not clearly discernable due
to a history suggestive of overlapping features with other
sleep disorders such as REM parasomnia, narcolepsy,
insomnia or psychiatric disturbance (category 3.c, n = 45).
A minority of patients belonged to the first and the
second category (n = 39) for which the diagnosis was
clearly delineated from the history alone; either patients
with uncomplicated NREM parasomnia (category 1,
n = 21) or patients with complicating associated features,
such as injurious behaviour (category 2.a, n = 10) or sus-
pected precipitants (category 2.b, n = 8).
None of the patients recruited fell within the category
2.c, since none of the patients were referred to us due to
failure to respond to conventional therapy.
There were 12 patients already diagnosed with epilepsy
but presenting with episodes at night suggestive of NREM
parasomnia behaviours (category 4), (Tables 1, 2).
NREM parasomnia findings
Overall PSG was decisive or supportive for a diagnosis of
NREM parasomnia in 75 of 124 overnight sleep studies
analysed (60.5 %) (Table 2).
As expected, PSG was positive for NREM parasomnia
(decisive or supportive) in a high proportion of cases with
typical clinical history, in particular when uncomplicated
(category 1; 95.2 %) but also in cases with typical but
complicated NREM parasomnia (category 2; 61.1 %).
Conversely within the categories with an atypical or
unusual history (category 3) or with a suspected coexis-
tence with epilepsy (category 4), NREM parasomnia was
found in a relatively lower proportion of patients (53.4 %
and 41.7 %, respectively).
Therefore the probability of having a sleep study posi-
tive for NREM parasomnia differed among the categories,
in keeping with the certainty of clinical diagnosis
(p = 0.001, Fisher’s exact) (Fig. 1).
Table 2 Demographics and NREM parasomnia PSG outcome for each clinical category
Categories Female (%) Onset B16 years (%)c PSG outcome
Mean age at admissiona Decisive (%) Supportive (%) Inconclusive (%) Total
1 61.9 100.0 31.1 ± 1 (22–49) 42.8 52.4 4.8 21
2.a 30.0 100.0 27.9 ± 2 (20–43) 50.0 10.0 40.0 10
2.b 50.0 100.0 37.1 ± 4 (26–61) 37.5 25.0 37.5 8
2.cb NA NA NA NA NA NA NA
3.a 66.7 0.0 41.4 ± 3 (28–67) 58.3 8.3 33.3 12
3.b 43.7 62.5 35.8 ± 3 (21–58) 43.8 31.2 25.0 16
3.c 46.7 44.1 41.7 ± 2 (18–80) 20.0 22.2 57.8 45
4 66.7 45.4 34.3 ± 2 (20–52) 16.7 25.0 58.3 12
Total 51.6 60.3 37.0 ± 1 (18–80) 33.9 26.6 39.5 124
a Data are given as mean ± SEM. Range is given within brackets
b None of the patients recruited fell within this category
c This information was missing for three patients
Fig. 1 The PSG results significantly varied among the categories and
the probability of having a test positive for NREM parasomnia
decreased with the uncertainty of the clinical diagnosis (p = 0.001)
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Age at onset
Although NREM parasomnias are typically thought to start
in childhood, the proportion of patients who had a PSG
positive for NREM parasomnia was similar for patients
with an onset before (67 %) or after (55 %) 16 years of
age.
Different/overlap diagnoses and precipitants findings
Among all 124 sleep studies analysed we found 9 (7.2 %)
overlapping diagnoses, where PSG showed features of
NREM parasomnia and another disorder (such as REM
behaviour disorder-RBD or epilepsy) and 11 (8.9 %) dif-
ferential diagnoses, where PSG was not supportive of
NREM parasomnia but was instead suggestive of a dif-
ferent sleep disorder.
We found a high proportion of potential precipitants
such as PLMs and obstructive respiratory events (hypop-
noea or apnoea) during sleep, which were deemed to be
clinically significant in 26 patients (21 %).
Overlapping, differential diagnoses or precipitating
factors were rare (9 %) within the category of clinically
typical NREM parasomnia (category 1), whereas they were
frequent (43 %) in the other categories (categories 2, 3 and
4 together, p \ 0.005) (Table 3).
Benzodiazepine and antidepressant consumption
26 out of 114 patients were taking BDZ and/or antide-
pressants (n = 5 BDZ; n = 10 SSRI; n = 2 tricyclics;
n = 6 SSRI and BDZ; n = 3 SSRI and tricyclics) at the
time of the sleep study. In 17 (65.4 %) of the 26 patients
taking the above medication, PSG did not show any fea-
tures diagnostic of NREM parasomnia (Table 4).
We found that a concomitant consumption of antide-
pressants and/or BDZ at the time of the sleep study affected
the outcome and significantly correlated with the proba-
bility to have a negative PSG (p = 0.01).
Diagnostic night evaluation
28 out of 124 patients studied were scheduled for and
underwent 2 nights of PSG. We found that 18 out of the 28
patients recorded for 2 night (64.2 %) had a positive PSG
(n = 12 NREM parasomnia alone; n = 4 overlap diagno-
ses; n = 2 different diagnosis) compared to the 68
(70.8 %) positive PSG out of 96 patients recorded for one
night only.
Therefore, we did not find any significant statistical
correlation between PSG outcome and number of recording
nights (p = 0.512).
Further, in 15 of the 18 patients above, the diagnosis was
made on the first night since the second night was not
diagnostic (n = 2) or did not to add any further informa-
tion compared to the previous (n = 13). Only in three
studies was the second night decisive for diagnosis
(Table 5).
Discussion
Polysomnography is a widely used diagnostic tool to assist
in the diagnosis of sleep disorders.
There is limited evidence regarding the utility of per-
forming PSG for the diagnosis of NREM parasomnia.
It has been two decades since Aldrich and Jahnke’s [28]
paper on the diagnostic value of PSG in patients with
suspected parasomnia.
They retrospectively studied 65 children and 57 adults
presenting with parasomnia-like episodes (both NREM and
REM) and found that PSG was overall useful and gave
diagnostic information in 65.5 % of patients. They con-
cluded that for patients with unexplained nocturnal
Table 3 Different/overlap
diagnoses and precipitants
found on PSG for each clinical
category
NAA nightmare-associated
arousal, E epilepsy, RBD REM
sleep behaviour disorder, PD
psychiatric disturbance
a Dissociative state and panic
attack, respectively
Categories Total of
patients
per
category
Patients with
overlap
diagnoses
Patient with different
diagnoses
Patients
with
precipitants
Total of precipitants,
overlap and different
diagnoses (%)
1 21 1 (RBD) 0 1 9.5
2.a 10 0 1 (NAA) 1 20.0
2.b 8 0 0 2 25.0
2.c 0 0 0 0 0.0
3.a 12 0 1 (PD)a 3 33.3
3.b 16 3 (1 RBD;2 E) 1 (E) 2 37.5
3.c 45 2 (RBD) 7 (5 RBD;1 NAA; 1 E) 12 46.7
4 12 3 (E) 1 (PD)a 5 75.0
Total 124 9 11 26 37.1
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movements or behaviour, either with or without known
epilepsy, the diagnostic yield with PSG is substantial. In
particular, Aldrich and Jahnke emphasised the superiority
of video PSG, compared to standard PSG without video
recording, to correlate behaviour with EEG while evalu-
ating parasomnias patients. Apart from this, only small
case series or case reports have been reported [25–27].
The lack of data regarding the role of PSG for this group
of people has led to a great divergence in clinical practice,
among different Sleep Centres, regarding the indications
for performing overnight sleep studies.
With this study, we assessed the utility of PSG in dif-
ferent clinical categories of patients with suspected NREM
parasomnia trying to clarify when this investigation should
be used and which measures should be adopted.
We found that, as previously suggested by Aldrich and
Jahnke [28], PSG combined with video-monitoring has a
high diagnostic value in people with suspected NREM
parasomnia giving the diagnosis in 76.5 % of the 124
studied patients. In particular, it confirmed the NREM
parasomnia diagnosis in 60.5 % of the cases and a different
or overlap diagnosis in 16 % of them, most of which were
found to be RBD (n = 9) or epilepsy (n = 7).
However, the value of PSG varied among the clinical
categories.
We found that when the diagnosis was clear and history
uncomplicated, PSG confirmed NREM parasomnia in
almost all patients (95 %) and very rarely showed any
underlying unsuspected precipitants or different sleep dis-
orders (5 %, respectively). It is of course also possible that
the patients with PSG did not identify any NREM para-
somnia might not have the disorder.
Conversely in people in whom the diagnosis was not
clinically obvious or the history showed some unusual
features, the probability of having NREM parasomnia
confirmed by PSG was significantly lower (53 %) but the
presence of unsuspected or unrecognised different diag-
noses (18 %) or potential precipitants (24 %) was rela-
tively high. Thus, whereas PSG has a limited value in
typical NREM parasomnias, it is advisable for people in
whom there is clinical uncertainty due to unusual features
in the history.
We also found that adulthood age of onset of NREM
parasomnia, often considered as an unusual feature [12],
did not affect the probability to find NREM parasomnia in
the PSG study. In fact NREM parasomnia was found in a
similar proportion of people with childhood (67 %) or
adulthood onset of the disorder (55 %). Therefore, age at
onset should not to be considered alone as a determining
feature against the clinical diagnosis.
Patients under investigation for suspected NREM para-
somnia often undergo more than one night of recording in
order to increase the probability of capturing events; this is
particularly so in those patients who are more challenging
or present with infrequent episodes. This is time and
resource consuming and also leads to increased inconve-
nience for patients. The advantage of longer recordings has
never been sufficiently investigated. In our group of
patients, we found that the second night rarely provided
any additional information since the proportion of positive
tests in people that underwent one night of recording
(70 %) was similar to that found in people with two nights
of PSG (64 %). In patients where the diagnosis was made,
this was usually already clear from the first night of the
recording (83 %). A single night’s admission would hence
appear to be sufficient for the majority of patients.
For some patients in our study, no episodes were
recorded even during longer admissions. Home video-
Table 4 Polysomnography outcome related to drug consumption in
26 patients taking potential outcome-affecting drugs
n = 26 patients
taking potential
outcome-affecting
drugsa
BDZ SSRI SNRI Tricyclics NREM
parasomnia
PSG
outcome
1 X X NEG
2 X X NEG
3 X NEG
4 X POS
5 X X POS
6 X X NEG
7 X POS
8 X NEG
9 X X POS
10 X POS
11 X POS
12 X POS
13 X POS
14 X NEG
15 X X NEG
16 X POS
17 X X NEG
18 X X NEG
19 X NEG
20 X NEG
21 X NEG
22 X X NEG
23 X NEG
24 X NEG
25 X NEG
26 X NEG
BDZ benzodiazepine-receptor agonists, SSRI serotonin reuptake
inhibitors, SNRI serotonin–norepinephrine reuptake inhibitors, PSG
polysomnography, POS positive, NEG negative
a This information was missing for 10 patient out of 124
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recording has recently been also shown to be an alternative,
useful tool on some occasions, in particular for people with
questionable or inconclusive PSG or where no episodes are
recorded in hospital, helping in appreciating the severity of
the episodes and for ruling out stereotyped behaviours [8,
32].
NREM parasomnia episodes can be precipitated by
external and internal factors in predisposed individuals. In
general, any factor that increases the proportion of SWS
(sleep deprivation or substances use) or sleep fragmenta-
tion with frequent arousals can facilitate events.
Obstructive respiratory events and PLMS have been
reported in NREM parasomnia patients [1, 6, 16, 25, 33,
34] as potential precipitating factors often causing arousal
or sleep disruption.
We found that, such comorbidities are not an infrequent
finding in adult patients evaluated for NREM parasomnia
(21 %) even in apparently asymptomatic patients.
Hence, the concomitant occurrence of PLMS or
obstructive respiratory events in this group of people
should not be underestimated, but their presence should be
sought by routine monitoring of leg EMG channels and
respiratory parameters.
Pharmacological treatment for NREM parasomnia is
usually not necessary for typical, infrequent and non-
injurious episodes. On the other hand, treatment may be
required for people in whom the episodes cause discomfort
or distress, such as excessive day-time somnolence or
injuries to themselves or bed-partner.
The most widely used drugs for treatment of NREM
parasomnia, when needed, are benzodiazepine and non-
benzodiazepine hypnotics (i.e. clonazepam, diazepam,
triazolam, zolpidem, etc.), tricyclics antidepressants (i.e.
imipramine) and SSRIs (i.e. paroxetine, trazodone).
Nevertheless the effect of these drugs on NREM and
NREM parasomnia remains controversial and their use is
Table 5 Diagnostic night
evaluation for 28 patients with
two consecutive recording
nights
E epilepsy, RBD REM sleep
behaviour disorder, I first, II
second
n = 28 patients that underwent
two recording nights
Category
belonging
NREM
parasomnia
found
Other diagnoses
found
Diagnostic
night
1 1 x I–II
2 2a x II
3 2a
4 3a x I
5 3a x I–II
6 3b x x (E) II
7 3b x (E ? exaggerated
hypnic jerks)
I
8 3b x x (E) I–II
9 3b x I–II
10 3b x I–II
11 3b x I–II
12 3c
13 3c x I–II
14 3c x II
15 3c x I–II
16 3c
17 3c x (E) I–II
18 3c
19 3c x I–II
20 3c
21 3c
22 3c x x (RBD) I–II
23 4
24 4
25 4 x I–II
26 4
27 4
28 4 x x (E) I–II
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mainly based on case reports since large randomised con-
trol trials have still not been made [35, 36].
We found that concomitant consumption of hypnotics,
tryciclics or SSRIs at the time of the recording significant
correlated with a negative PSG result (p = 0.01), reducing
the possibility to capture the events and therefore the yield
of the test.
There are a number of limitations to our study. First, it is
a retrospective study and thus clinical categorisation was
based on previously documented clinical histories that
might depend on different clinician experience and
perspectives.
For the same reason, information was missing for a few
patients regarding age of onset (n = 3) or drug consump-
tion (n = 10).
Patients were recruited from a tertiary specialty clinic
and may not be representative of all patients with NREM
parasomnias. Further, in the absence of validated methods
for detecting NREM parasomnias with PSG, the prevalence
of suggestive features in our population may be overesti-
mated; for example, spontaneous arousals from deep sleep
are characteristic but not specific of this disorder.
Although the role of PSG for diagnosis of NREM
parasomnias is also relevant for children, care should be
taken in translating our findings to the pediatric population.
Indeed in children, the proportion of typical NREM para-
somnias is higher and certain alternative diagnoses such as
RBD are far less common. Therefore the proportion of
different diagnoses found on PSG might be lower. How-
ever, in unusual cases, PSG is critical to rule out epilepsy
and precipitants in selected patients.
In conclusion, polysomnography has a high diagnostic
yield in adults with suspected NREM parasomnia and is
particularly useful to assist the diagnosis in people with an
unusual or complicated history. Hence, when the clinical
presentation alone does not allow a clear diagnosis an
overnight evaluation of the episodes with comprehensive
video-monitoring is essential. This should be performed for
one night only in the first instance, with leg electrodes and
measurement of respiratory parameters, and after benzo-
diazepine and antidepressant withdrawal, if at all possible.
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